


MOUNT SINAI LIVER
CANCER PROGRAM

16TH ANNIVERSARY

LIVE VIRTUAL ACTIVITY

LIVER CANCER:
***Advances in Science and
Clinical Management***

FRIDAY, DECEMBER 17, 2021



Program Director

Josep M. Llovet, MD, PhD

Co-Director, Mount Sinai Liver Cancer Program

Sponsored by

Mount Sinai Liver Cancer Program



**Mount
Sinai**

The Tisch Cancer Institute


1st NCI recognized Liver Cancer Program in the U.S.

LIVER CANCER: Advances in Science and Clinical Management

FRIDAY, DECEMBER 17, 2021

PROGRAM

- 8:30 – 9:00am** **Registration**
- 9:00 – 9:10am** **Welcome and Opening**
Ramon Parsons, MD, PhD, Director, Tisch Cancer Institute. Ward-Coleman Chair in Cancer Research. Director, Mount Sinai Cancer, Mount Sinai Health System
Chair, Department of Oncological Sciences
- 9:10 – 9:40am** **Achievements of Mount Sinai Liver Cancer Program 2005-2021**
Josep M. Llovet, MD, PhD, Co-Director, Mount Sinai Liver Cancer Program, Division of Liver Diseases
- 9:40 – 10:20am** **Hans Popper Lecture**
Introduction: Josep M. Llovet, MD, PhD, Co-Director, Mount Sinai Liver Cancer Program, Division of Liver Diseases
Epidemiology and early detection of HCC
Amit Singal, MD, Medical Director, Liver Tumor Program, Clinical Chief of Hepatology
The University of Texas Southwestern Medical Center, Dallas, Texas
- 10:20 – 10:40am** **Coffee Break**
-
- 10:40 – 11:50am** **PATHOGENESIS OF LIVER CANCER**
Chairman: Scott Friedman, MD, Dean of Therapeutic Discovery, Co-Director, Mount Sinai Liver Cancer Program
- 10:40 – 11:10am** **Overview: from NASH to NASH-HCC**
Scott Friedman, MD, Dean of Therapeutic Discovery, Co-Director Mount Sinai Liver Cancer Program
- 11:10 – 11:30am** **Molecular pathology of HCC and iCCA**
M. Isabel Fiel, MD, Pathology, Molecular & Cell Based Medicine, Mount Sinai Liver Cancer Program
- 11:30 – 11:50am** **Cholangiocarcinoma: Novel insights into the immune subtypes**
Daniela Sia, PhD, Mount Sinai Liver Cancer Program, Division of Liver Diseases
- 11:50 – 12:20pm** **Lunch**
-
- 12:20 – 2:00pm** **MANAGEMENT OF EARLY- INTERMEDIATE LIVER CANCER**
Chairman: Myron Schwartz, MD, Clinical Director, Mount Sinai Liver Cancer Program, Director of Liver Surgery, Recanati/Miller Transplantation Institute
- 12:20 – 12:40pm** **Neoadjuvant immunotherapy treatment in HCC**
Thomas Marron, MD, PhD, Director, Early Phase Trials Unit, Tisch Cancer Institute, Department of Hematology and Medical Oncology



- 12:40 – 1:00pm** **Are surgical vs medical indications changing for liver cancer?**
Myron Schwartz, MD, Clinical Director, Mount Sinai Liver Cancer Program, Director of Liver Surgery, Recanati/Miller Transplantation Institute
- 1:00 – 1:20pm** **Resection vs liver transplantation for intrahepatic cholangiocarcinoma**
Parissa Tabrizian, MD, MSc, Mount Sinai Liver Cancer Program, Department of Liver Surgery, Recanati/Miller Transplantation Institute
- 1:20 – 1:40pm** **Chemoembolization (TACE) combined with systemic therapies**
Edward Kim, MD, Director of Interventional Oncology, Assistant Professor of Radiology and Surgery, Division of Vascular and Interventional Radiology, Mount Sinai Liver Cancer Program
- 1:40 – 2:00pm** **Coffee Break**
-
- 2:00 – 3:30pm** **MANAGEMENT OF ADVANCED LIVER CANCER**
Chairman: Josep M Llovet, MD, PhD, Co-Director Mount Sinai Liver Cancer Program, Division of Liver Diseases
- 2:00 – 2:30pm** **Overview: Molecular and immune therapies in advanced HCC**
Josep M Llovet, MD, PhD, Co-Director Mount Sinai Liver Cancer Program, Division of Liver Diseases
- 2:30 – 2:50pm** **Biomarker development in HCC: anything ready for prime time?**
Augusto Villanueva, MD, PhD, Mount Sinai Liver Cancer Program, Division of Liver Diseases
- 2:50 – 3:10pm** **Overview of systemic therapies for intrahepatic cholangiocarcinoma**
Deirdre Cohen, MD, MS, Director of the Gastrointestinal Oncology Program, Medical Director of the Cancer Clinical Trials Office, Tisch Cancer Institute, Department of Hematology and Medical Oncology
- 3:10 – 3:30pm** **Coffee Break**
-
- 3:30 – 4:10pm** **NOVEL TARGETS AND PRE-CLINICAL MODELS FOR LIVER CANCER**
Chairman: Samuel Waxman, MD, Distinguished Service Professor of Medicine, Department of Hematology and Medical Oncology, Department of Oncological Sciences
- 3:30 – 3:50pm** **Novel mechanisms of immune evasion in HCC**
Amaia Lujambio, PhD, Department of Oncological Sciences
- 3:50 – 4:10pm** **Discovery of Wnt inhibitors in pre-clinical models of HCC**
Ernesto Guccione, PhD, Department of Oncological Sciences
- 4:20pm** **Closing Remarks**

Conference Information

<https://mssm.cloud-cme.com> • Office of CME email: cme@mssm.edu

PROGRAM DIRECTOR

JOSEP M. LLOVET, MD, PHD

Co-Director Mount Sinai Liver Cancer Program, Professor of Medicine,
Division of Liver Diseases

PROGRAM CHAIRS

SCOTT FRIEDMAN, MD

Dean of Therapeutic Discovery, Co-Director Mount Sinai Liver Cancer Program,
Division of Liver Diseases

MYRON E. SCHWARTZ, MD

Clinical Director, Mount Sinai Liver Cancer Program, Director of Liver Surgery,
Recanati/Miller Transplantation Institute

SAMUEL WAXMAN, MD

Distinguished Service Professor of Medicine, Department of Hematology and
Medical Oncology, Department of Oncological Sciences

GUEST FACULTY

AMIT SINGAL, MD

Medical Director, Liver Tumor Program, Clinical Chief of Hepatology
The University of Texas Southwestern Medical Center, Dallas, Texas

HOST FACULTY

DEIRDRE COHEN, MD, MS

Director of the Gastrointestinal Oncology Program, Medical Director of the Cancer Clinical
Trials Office, Tisch Cancer Institute, Department of Hematology and Medical Oncology

ERNESTO GUCCIONE, PhD

Department of Oncological Sciences

M. ISABEL FIEL, MD

Pathology, Molecular & Cell Based Medicine, Mount Sinai Liver Cancer Program

SCOTT FRIEDMAN, MD

Dean of Therapeutic Discovery, Co-Director Mount Sinai Liver Cancer Program,
Division of Liver Diseases

EDWARD KIM, MD

Director of Interventional Oncology, Assistant Professor of Radiology and Surgery,
Division of Vascular and Interventional Radiology, Mount Sinai Liver Cancer Program

JOSEP M LLOVET, MD, PhD

Co-Director Mount Sinai Liver Cancer Program, Professor of Medicine,
Division of Liver Diseases

AMAIA LUJAMBIO, PhD

Department of Oncological Sciences

THOMAS MARRON, MD, PhD

Director, Early Phase Trials Unit, Tisch Cancer Institute, Department of Hematology and
Medical Oncology

RAMON PARSONS, MD, PhD

Director, Tisch Cancer Institute, Ward-Coleman Chair in Cancer Research,
Director, Mount Sinai Cancer, Mount Sinai Health System
Chair, Department of Oncological Sciences

MYRON SCHWARTZ, MD

Clinical Director, Mount Sinai Liver Cancer Program, Director of Liver Surgery,
Recanati/Miller Transplantation Institute

DANIELA SIA, PhD

Mount Sinai Liver Cancer Program, Division of Liver Diseases

PARISSA TABRIZIAN, MD

Mount Sinai Liver Cancer Program, Department of Liver Surgery,
Recanati/Miller Transplantation Institute

AUGUSTO VILLANUEVA, MD, PhD

Mount Sinai Liver Cancer Program, Division of Liver Diseases

SAMUEL WAXMAN, MD

Distinguished Service Professor of Medicine, Department of Hematology and
Medical Oncology, Department of Oncological Sciences

Target Audience

Hepatologists and Gastroenterologist, Oncologists, Surgeons, Radiologist, Pathologists and Basic Scientists interested in liver cancer from the New York Area and beyond.

Accreditation

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The Icahn School of Medicine at Mount Sinai designated this internet live activity for a maximum of 6.0 *AMA PRA Category 1 Credit(s)*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Activity Description

This conference will assemble multidisciplinary experts on chronic liver diseases, hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) from the Mount Sinai Liver Cancer Program and one outstanding invited lecturer. The meeting is intended to provide a summary of the state-of-the-art knowledge of the novel advancements reported in 2021 on the pathogenesis and clinical management of liver cancer, including the research conducted in Mount Sinai.

Activity Learning Objectives

- Understand the epidemiology and disparities of liver cancer in the US.
- Review the current role of surgical and loco-regional treatments for liver cancer.
- Critical review of molecular therapies and SBRT in the management of advanced HCC.
- Understand the molecular rationale for immune therapies in HCC.

Special Needs

The Icahn School of Medicine at Mount Sinai is in full compliance with provisions of the Americans with Disabilities Act (ADA) and is accessible for individuals with special needs. If you would like to attend this conference and require any special needs or accommodations please contact the Page and William Black Post-Graduate School of Medicine at cme@mssm.edu.

Faculty Disclosure

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-provided educational activities. All faculty participating in the planning or implementation of a provided activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course materials.

Registration

<https://mssm.cloud-cme.com>

Registration Fee

Registration is complimentary.

Acknowledgement

This activity is made possible in part by educational grants from:

Bayer HealthCare, Boston Scientific, Celsion, Eisai, Inc., and Merck Sharp & Dohme Corp.

Icahn School of Medicine at Mount Sinai
The Page and William Black Post Graduate School
One Gustave L. Levy Place, Box 1193
New York, NY 10029-6574

**MOUNT SINAI LIVER
CANCER PROGRAM**

16TH ANNIVERSARY

***LIVER CANCER:
Advances in Science and
Clinical Management***



Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai

Complimentary Online Registration